TOBAM’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,622
| Closed | -$223K | – | 257 |
|
|
2024
Q4 | $223K | Sell |
1,622
-541
| -25% | -$74.4K | 0.07% | 151 |
|
|
2024
Q3 | $323K | Hold |
2,163
| – | – | 0.06% | 156 |
|
|
2024
Q2 | $295K | Hold |
2,163
| – | – | 0.05% | 155 |
|
|
2024
Q1 | $327K | Buy |
2,163
+630
| +41% | +$95.2K | 0.03% | 176 |
|
|
2023
Q4 | $193K | Sell |
1,533
-277
| -15% | -$34.9K | 0.02% | 226 |
|
|
2023
Q3 | $169K | Hold |
1,810
| – | – | 0.01% | 244 |
|
|
2023
Q2 | $162K | Hold |
1,810
| – | – | 0.01% | 273 |
|
|
2023
Q1 | $194K | Sell |
1,810
-718
| -28% | -$77K | 0.01% | 223 |
|
|
2022
Q4 | $309K | Buy |
2,528
+526
| +26% | +$64.3K | 0.02% | 174 |
|
|
2022
Q3 | $207K | Buy |
2,002
+564
| +39% | +$58.3K | 0.01% | 210 |
|
|
2022
Q2 | $134K | Buy |
1,438
+1,217
| +551% | +$113K | 0.01% | 277 |
|
|
2022
Q1 | $26K | Sell |
221
-883
| -80% | -$104K | ﹤0.01% | 416 |
|
|
2021
Q4 | $149K | Sell |
1,104
-1,816
| -62% | -$245K | 0.01% | 211 |
|
|
2021
Q3 | $465K | Sell |
2,920
-1,149
| -28% | -$183K | 0.02% | 149 |
|
|
2021
Q2 | $535K | Buy |
4,069
+907
| +29% | +$119K | 0.02% | 148 |
|
|
2021
Q1 | $408K | Buy |
3,162
+828
| +35% | +$107K | 0.02% | 153 |
|
|
2020
Q4 | $389K | Sell |
2,334
-117
| -5% | -$19.5K | 0.02% | 155 |
|
|
2020
Q3 | $378K | Buy |
2,451
+202
| +9% | +$31.2K | 0.02% | 143 |
|
|
2020
Q2 | $333K | Buy |
2,249
+558
| +33% | +$82.6K | 0.02% | 112 |
|
|
2020
Q1 | $190K | Sell |
1,691
-96
| -5% | -$10.8K | 0.02% | 122 |
|
|
2019
Q4 | $249K | Sell |
1,787
-23
| -1% | -$3.21K | 0.02% | 103 |
|
|
2019
Q3 | $174K | Buy |
1,810
+446
| +33% | +$42.9K | 0.01% | 101 |
|
|
2019
Q2 | $157K | Buy |
+1,364
| New | +$157K | 0.01% | 102 |
|